Psychiatric side effects of interferon-β in multiple sclerosis

被引:64
作者
Goeb, JL
Even, C
Nicolas, G
Gohier, B
Dubas, F
Garré, JB
机构
[1] CHRU, Serv Psychiat Enfant Adolescent, F-59037 Lille, France
[2] Ctr Hosp St Anne, Clin Malad Mentales Encephale, Paris, France
[3] CHU Angers, Neurol Serv, Angers, France
[4] CHU Angers, Psychiat Serv, Angers, France
关键词
interferon; multiple sclerosis; side effects;
D O I
10.1016/j.eurpsy.2005.09.013
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Psychiatric disorders, especially depression, are frequent in patients with multiple sclerosis (MS). They are attributed both to the psychosocial impact of a chronic, usually progressive, disabling illness and to cerebral demyelination. Besides, drugs such as corticosteroids and possibly interferon (IFN) may also have depressogenic effects. Major depressive disorders and/or suicidal ideation are a major concern and efforts to identify and minimize these reactions are of much importance. Psychiatric side effects, particularly depression, are widely reported with IFN-alpha and have been suspected with IFN-beta but are not yet fully established. Our review of the literature revealed that most studies discard an association between IFN-beta and depression or suicide. However, few patients, especially those with a history of depression, might be at higher risk for depression when treated with IFN-beta. Overall, considering the uncertainty of a link between IFN-beta and depression and/or suicide, as well as the complete remission of psychiatric complications after IFN discontinuation and/or antidepressant treatment, physicians should closely monitor the psychiatric status of patients, but Should not refrain from including them in IFN-beta treatment programs, even when they have past or present depression. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码:186 / 193
页数:8
相关论文
共 84 条
[1]  
Alarcia R, 2004, NEUROLOGIA, V19, P364
[2]   Interferon-β affects the tryptophan metabolism in multiple sclerosis patients [J].
Amirkhani, A ;
Rajda, C ;
Arvidsson, B ;
Bencsik, K ;
Boda, K ;
Seres, E ;
Markides, KE ;
Vécsei, L ;
Bergquist, J .
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (08) :625-631
[3]   PSYCHIATRIC ASPECTS OF MULTIPLE-SCLEROSIS [J].
BAL, MAA ;
VAZQUEZBARQUERO, JL ;
PENA, C ;
MIRO, J ;
BERCIANO, JA .
ACTA PSYCHIATRICA SCANDINAVICA, 1991, 83 (04) :292-296
[4]   Managing the adverse effects of interferon-β therapy in multiple sclerosis [J].
Bayas, A ;
Rieckmann, P .
DRUG SAFETY, 2000, 22 (02) :149-159
[5]  
Beck A.T., 1987, BECK DEPRESSION INVE
[6]   Biologic role of interferon beta in multiple sclerosis [J].
Billiau, A ;
Kieseier, BC ;
Hartung, HP .
JOURNAL OF NEUROLOGY, 2004, 251 (Suppl 2) :10-14
[7]   VALIDITY OF THE CENTER FOR EPIDEMIOLOGICAL-STUDIES DEPRESSION SCALE IN ARTHRITIS POPULATIONS [J].
BLALOCK, SJ ;
DEVELLIS, RF ;
BROWN, GK ;
WALLSTON, KA .
ARTHRITIS AND RHEUMATISM, 1989, 32 (08) :991-997
[8]   Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus [J].
Bonaccorso, S ;
Marino, V ;
Biondi, M ;
Grimaldi, F ;
Ippoliti, F ;
Maes, M .
JOURNAL OF AFFECTIVE DISORDERS, 2002, 72 (03) :237-241
[9]  
Bonar SA, 2002, N AM J FISH MANAGE, V22, P96, DOI 10.1577/1548-8675(2002)022<0096:EOTGCO>2.0.CO
[10]  
2